Loading
LOADING
Every GH secretagogue study runs against somatostatin tone. What the peptide is, how its five receptor subtypes are distributed, how it produces pulsatile GH release, and why it is the main confounder in secretagogue assay design.
Somatostatin is a cyclic peptide hormone that inhibits the release of growth hormone, insulin, glucagon, and several gastrointestinal hormones, and it is the reason growth hormone is released in pulses rather than continuously. It exists in two active forms cleaved from the same precursor: somatostatin-14 (SST-14), a 14-residue peptide with the sequence Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys, cyclized by a disulfide bond between cysteine 3 and cysteine 14, and somatostatin-28 (SST-28), which carries a 14-residue N-terminal extension. The Phe-Trp-Lys-Thr motif at positions 7 to 10 inside the ring is the receptor-binding core, and it is the segment that all synthetic analogs preserve. The glossary entry gives the one-paragraph version; this article covers the biology that every GH secretagogue study has to account for.
The somatostatin relevant to growth hormone comes from neurons in the periventricular nucleus of the hypothalamus, which project to the median eminence and release the peptide into the hypophyseal portal blood that bathes the anterior pituitary. Somatostatin is also produced by delta cells in the pancreatic islets, by D cells in the gastric and intestinal mucosa, and by neurons throughout the central nervous system, where it acts locally as a paracrine inhibitor and neuromodulator. SST-14 predominates in the hypothalamus and pancreas; SST-28 predominates in the gut. Both forms are cleared within one to three minutes in circulation, which is why the endogenous peptide cannot be studied as a systemic agent and why the long-acting synthetic analogs exist.
Somatostatin acts through five class A G-protein-coupled receptors, SSTR1 through SSTR5, all coupled to Gi/o, and all inhibiting adenylyl cyclase and reducing cyclic AMP. Beyond that shared mechanism they differ in distribution and in secondary signaling: SSTR2 and SSTR5 additionally activate inwardly rectifying potassium channels and inhibit voltage-gated calcium channels, which is the direct route by which they suppress hormone exocytosis. Pituitary somatotrophs express predominantly SSTR2 and SSTR5, with SSTR2 the dominant subtype mediating growth hormone inhibition in most published models. SSTR1 and SSTR3 are expressed more widely in the brain and in tumors; SSTR4 is prominent in the lung and in certain neuronal populations. SST-14 and SST-28 bind all five subtypes, with SST-28 showing higher affinity at SSTR5. Subtype selectivity is the design axis for the synthetic analogs.
Growth hormone is released in discrete pulses, several per day with the largest during early sleep, because two hypothalamic signals with opposite actions alternate at the somatotroph. Growth hormone-releasing hormone (GHRH) from the arcuate nucleus stimulates synthesis and release through the Gs-coupled GHRH receptor. Somatostatin from the periventricular nucleus inhibits release through the Gi-coupled SSTR2 and SSTR5. The two neuron populations are reciprocally connected and respond to growth hormone and IGF-1 feedback, so somatostatin tone rises after a pulse and falls before the next one. A pulse occurs when somatostatin tone drops and GHRH is present; the trough between pulses is a period of somatostatin dominance. This push-pull architecture is why continuous GHRH exposure in research models still produces intermittent growth hormone output: somatostatin withdrawal, not GHRH arrival, times the pulse. The GH secretagogues guide covers the compounds that act on the GHRH side.
Ghrelin and its synthetic mimetics (ipamorelin, GHRP-2, GHRP-6, and the non-peptide MK-677) act at the growth hormone secretagogue receptor GHS-R1a on somatotrophs and in the hypothalamus. Published work attributes part of their effect to functional antagonism of somatostatin: GHS-R1a agonists have been reported to stimulate GHRH neurons and to reduce somatostatin release, in addition to acting directly on the somatotroph through Gq and calcium. This is one explanation for the synergy observed when a GHRH analog and a ghrelin mimetic are applied together in pituitary cell models: the GHRH analog supplies the stimulus and the ghrelin mimetic lowers the brake. The GHRH analogs versus ghrelin mimetics article covers the two classes in detail.
The native peptide's short half-life led to cyclic analogs that preserve the Phe-Trp-Lys-Thr core in a smaller, protease-resistant ring. Octreotide is an 8-residue cyclic peptide with D-tryptophan and a reduced C-terminal threoninol, selective for SSTR2 with lesser SSTR5 and SSTR3 activity, and a half-life of roughly 90 to 120 minutes. Lanreotide is a similar SSTR2-preferring octapeptide formulated for extended release. Pasireotide is a cyclohexapeptide with broader activity across SSTR1, SSTR2, SSTR3, and SSTR5, with particularly high SSTR5 affinity. All three are approved pharmaceutical products in various jurisdictions for specific indications; that regulatory fact is noted here because these analogs are the standard reference tools in somatostatin receptor research, used to dissect which subtype mediates a given effect. They are not research-market peptides in the sense used elsewhere on this site.
Any assay measuring growth hormone release in response to a secretagogue is measuring the net of stimulation and somatostatin inhibition, and somatostatin tone varies with time of day, feeding state, sleep, stress, age, sex, and prior growth hormone exposure. A secretagogue applied during a somatostatin trough produces a large response; the same compound applied during a peak produces a small one. This is the source of the high variability in growth hormone response reported across published secretagogue studies, and it is why well-designed protocols control timing, fast participants or animals, and often include a somatostatin-suppressing or somatostatin-antagonist condition to unmask the compound's maximal effect. In isolated pituitary cell models, the absence of hypothalamic somatostatin is itself a difference from the intact system that limits translation. Comparing two secretagogues from separate studies without accounting for somatostatin tone is comparing two different experiments.
Every compound in the growth hormone research category acts on one side of the somatostatin balance. GHRH analogs (sermorelin, CJC-1295, tesamorelin) supply the stimulus. Ghrelin mimetics supply stimulus and partially lift the brake. Somatostatin and its analogs are the brake itself. Understanding which side a compound acts on, and what the brake is doing at the time of measurement, is the minimum needed to read a growth hormone secretagogue study correctly.
This article describes somatostatin's structure and physiology for educational purposes and does not describe or endorse any use of any compound. It is not medical advice.
Still have questions?
ASK AXIOM ABOUT THIS TOPIC →